Comparative Pharmacology
Head-to-head clinical analysis: ACETAZOLAMIDE versus KEVEYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAZOLAMIDE versus KEVEYIS.
ACETAZOLAMIDE vs KEVEYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Keveyis (dichlorphenamide) is a carbonic anhydrase inhibitor. It reduces the frequency of attacks in primary hyperkalemic periodic paralysis by decreasing intracellular pH, which stabilizes muscle cell membranes and reduces potassium efflux from muscle cells.
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
50 mg orally twice daily with food; may increase to 100 mg twice daily after 2 weeks if needed.
None Documented
None Documented
Clinical Note
moderateAcetazolamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Atorvastatin."
Clinical Note
moderateAcetazolamide + Diclofenamide
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Diclofenamide."
Clinical Note
moderateAcetazolamide + Fosphenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Fosphenytoin."
Clinical Note
moderateTerminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
Terminal elimination half-life: 15–20 hours following a single oral dose; at steady state, half-life 42–80 hours (mean ~60 h) due to dose-dependent kinetics.
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Primarily renal: unchanged drug accounts for ~82% of dose in urine; fecal excretion <5%; minor hepatic metabolism.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Acetazolamide + Phenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Phenytoin."